Apparatus

According to Telegraph, a new study shows that human doctors will still outperform "robot doctors" in surgery. Compared with robots, human doctors need shorter time to complete surgery, and the error rate is not high.

Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).

Stroke is the main cause of disability in Americans. More than 6.5 million Americans survive stroke every year, and most of them cannot fully recover their walking ability. Experts said that because of the difficulty in walking, these patients would not even go out to the store to buy things, but they were inactive for a long time, which led to other health problems and a spiral decline in their quality of life.

Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."

Under the terms of the collaboration agreement, GenKOre will receive up to US$300 million, including upfront fees, fees for exercising its option, and milestone payments for successfully reaching development and commercialisation milestones against two in vivo disease targets.

Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.

On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.

A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.

PET/CT and PET/MRI, the world's leading-edge imaging screening devices, have extremely significant advantages in the early screening and diagnosis of a wide range of benign and malignant tumours throughout the body, the nervous system and the cardiovascular system, and can detect tumours as small as millimetres, especially useful for the early detection and treatment of liver cancer, breast cancer and pancreatic cancer. Translated with www.DeepL.com/Translator (free version)

The "me better" strategy has always been a great story for pharmaceutical companies.